“Three-Dimensional Breast Cancer Spheroids” submitted by radiotherapeutics researcher Debjani Pal is stunning. Brilliant blue dots pop from an electric sphere threaded with bright colors: greens, aqua, hot pink and red.
In fiscal year 2023 — Oct. 1–Sept. 30, 2023 — Oak Ridge National Laboratory was awarded more than $8 million in technology maturation funding through the Department of Energy’s Technology Commercialization Fund, or TCF.
Nonfood, plant-based biofuels have potential as a green alternative to fossil fuels, but the enzymes required for production are too inefficient and costly to produce. However, new research is shining a light on enzymes from fungi that could make biofuels economically viable.
How did we get from stardust to where we are today? That’s the question NASA scientist Andrew Needham has pondered his entire career.
ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
A team led by the U.S. Department of Energy’s Oak Ridge National Laboratory demonstrated the viability of a “quantum entanglement witness” capable of proving the presence of entanglement between magnetic particles, or spins, in a quantum material.
ORNL's Larry Baylor and Andrew Lupini have been elected fellows of the American Physical Society.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.